Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study to Validate the Instructions for Use of TOBI® Podhaler™ in Cystic Fibrosis Patients

Phase 4

Completed

Conditions: Cystic Fibrosis

Interventions: Drug: Placebo
Device: Tobi Podhaler

First Posted Date: 2014-06-30

Last Posted Date: 2016-05-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 45

Registration Number: NCT02178540

Locations: 🇺🇸
Novartis Investigative Site, Houston, Texas, United States

Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD

Phase 4

Completed

Conditions: Neovascular Age-related Macular Degeneration

Interventions: Drug: Ranibizumab

First Posted Date: 2014-06-11

Last Posted Date: 2019-02-15

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 103

Registration Number: NCT02161575

Locations: 🇬🇧
Novartis Investigative Site, York, United Kingdom

Dose Escalation Study of LGH447 in Japanese Patients With Relapsed and/or Refractory Hematologic Malignancies

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: LGH447

First Posted Date: 2014-06-11

Last Posted Date: 2020-12-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 13

Registration Number: NCT02160951

Locations: 🇯🇵
Novartis Investigative Site, Okayama-city, Okayama, Japan

OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticaria (CSU) Patients

Phase 3

Completed

Conditions: Chronic Spontaneous Urticaria

Interventions: Drug: omalizumab

First Posted Date: 2014-06-11

Last Posted Date: 2018-09-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 314

Registration Number: NCT02161562

Locations: 🇵🇦
Novartis Investigative Site, Panama, Panama

BGJ398 for Patients With Tumors With FGFR Genetic Alterations

Phase 2

Terminated

Conditions: Solid Tumor
Hematologic Malignancies

Interventions: Drug: BGJ398

First Posted Date: 2014-06-10

Last Posted Date: 2019-06-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 84

Registration Number: NCT02160041

Locations: 🇺🇸
Chattanooga Oncology and Hematology Assoicates, PC Chattanooga Oncology, Chattanooga, Tennessee, United States
🇺🇸
Virginia Cancer Specialists Fairfax Northern Virginia, Fairfax, Virginia, United States
🇺🇸
Duke University Medical Center Seeley G. Mudd Bldg., Durham, North Carolina, United States

and more 53 locations

A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)

Phase 3

Terminated

Conditions: Thrombocytopaenia

Interventions: Drug: Eltrombopag
Drug: Placebo
Drug: Azacitidine

First Posted Date: 2014-06-09

Last Posted Date: 2017-12-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 356

Registration Number: NCT02158936

Locations: 🇹🇷
Novartis Investigative Site, Samsun, Turkey

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis

Phase 3

Completed

Conditions: Spondylitis, Ankylosing

Interventions: Biological: Secukinumab
Biological: Placebo

First Posted Date: 2014-06-09

Last Posted Date: 2019-04-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 350

Registration Number: NCT02159053

Locations: 🇬🇧
Novartis Investigative Site, Wolverhampton, United Kingdom

Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox.

Phase 2

Terminated

Conditions: High Risk MDS

Interventions: Drug: Azacitidine plus Deferasirox
Drug: Azacitidine

First Posted Date: 2014-06-09

Last Posted Date: 2017-04-04

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1

Registration Number: NCT02159040

Locations: 🇺🇸
Rochester General Hospital / Lipson Cancer Center Lipson Cancer Center, Rochester, New York, United States
🇺🇸
Utah Cancer Specialists IHO Corp, Salt Lake City, Utah, United States
🇺🇸
City of Hope National Medical Center Oncology, Duarte, California, United States

and more 3 locations

Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.

Phase 1

Completed

Conditions: Advanced or Metastatic Breast Cancer

Interventions: Drug: LEE011
Drug: Buparlisib
Drug: Letrozole

First Posted Date: 2014-06-03

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 13

Registration Number: NCT02154776

Locations: 🇺🇸
Horizon Oncology Center SC, Lafayette, Indiana, United States
🇺🇸
Medical University of South Carolina SC, Charleston, South Carolina, United States
🇺🇸
South Texas Accelerated Research Therapeutics SC, San Antonio, Texas, United States

and more 3 locations

Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery

Phase 2

Completed

Conditions: Muscle Wasting (Atrophy) After Hip Fracture Surgery

Interventions: Other: placebo
Drug: bimagrumab

First Posted Date: 2014-06-02

Last Posted Date: 2020-08-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 251

Registration Number: NCT02152761

Locations: 🇬🇧
Novartis Investigative Site, Bath, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy